Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07712562 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes

Study acronym: BMF
StatusNot Yet Recruiting
PhasePhase 1/2
SponsorDren Bio
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 2 of 2 changed
See other at-risk trials from Dren Bio

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Study sites: 9 to 10
    • Eligibility criteria shortened, about 62 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Dren Bio
4 trials monitored
See 1 trial at risk
This is a multicenter, open-label, Phase 1/2 basket study to evaluate the safety and efficacy of Dibotatug (DR-01) in adults with Bone Marrow Failure syndromes.
Trial Details
NCT Number NCT07712562
Lead Sponsor Dren Bio
Conditions
(from sponsor)		 Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse, Severe Aplastic Anemia, Refractory, Non-severe Aplastic Anemia
Related terms Anemia, Aplastic, Bone Marrow Failure Disorders, Hematologic Diseases, Leukocyte Disorders, Pancytopenia, Recurrence
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov